Literature DB >> 15451594

Aerosolization properties, surface composition and physical state of spray-dried protein powders.

Cynthia Bosquillon1, Paul G Rouxhet, François Ahimou, Denis Simon, Christine Culot, Véronique Préat, Rita Vanbever.   

Abstract

Powder aerosols made of albumin, dipalmitoylphosphatidylcholine (DPPC) and a protein stabilizer (lactose, trehalose or mannitol) were prepared by spray-drying and analyzed for aerodynamic behavior, surface composition and physical state. The powders exited a Spinhaler inhaler as particle aggregates, the size of which depending on composition, spray-drying parameters and airflow rate. However, due to low bulk powder tap density (<0.15 g/cm3), the aerodynamic size of a large fraction of aggregates remained respirable (<5 microm). Fine particle fractions ranged between 21% and 41% in an Andersen cascade impactor operated at 28.3 l/min, with mannitol and lactose providing the most cohesive and free-flowing powders, respectively. Particle surface analysis by X-ray photoelectron spectroscopy (XPS) revealed a surface enrichment with DPPC relative to albumin for powders prepared under certain spray-drying conditions. DPPC self-organized in a gel phase in the particle and no sugar or mannitol crystals were detected by X-ray diffraction. Water sorption isotherms showed that albumin protected lactose from moisture-induced crystallization. In conclusion, a proper combination of composition and spray-drying parameters allowed to obtain dry powders with elevated fine particle fractions (FPFs) and a physical environment favorable to protein stability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451594     DOI: 10.1016/j.jconrel.2004.07.022

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  22 in total

1.  New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

Review 2.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

3.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

Review 4.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

5.  Microparticles for inhalational delivery of antipseudomonal antibiotics.

Authors:  Michael D Tsifansky; Yoon Yeo; Oleg V Evgenov; Evangelia Bellas; John Benjamin; Daniel S Kohane
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

6.  Effects of Temperature and Humidity on Laser Diffraction Measurements to Jet Nebulizer and Comparison with NGI.

Authors:  Xinghan Song; Junhua Hu; Shuyao Zhan; Rui Zhang; Wen Tan
Journal:  AAPS PharmSciTech       Date:  2015-07-14       Impact factor: 3.246

7.  Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.

Authors:  Waseem Kaialy; Gary P Martin; Martyn D Ticehurst; Paul Royall; Mohammad A Mohammad; John Murphy; Ali Nokhodchi
Journal:  AAPS J       Date:  2010-11-06       Impact factor: 4.009

8.  Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.

Authors:  Xiaojian Li; Heidi M Mansour
Journal:  AAPS PharmSciTech       Date:  2011-10-25       Impact factor: 3.246

9.  Chapter 9 - Nanoliposomal dry powder formulations.

Authors:  Gaurang Patel; Mahavir Chougule; Mandip Singh; Ambikanandan Misra
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

10.  Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Authors:  Yan Yang; Michael D Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt; Yoon Yeo
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.